rit with -ibritumomab tiuxetan in follicular non-hodgkin lymphoma evaluation of recent outcomes in a single institution罗切斯特理工学院的航拍与-ibritumomab tiuxetan在最近的滤泡性非霍奇金淋巴瘤评估结果在一个单一的机构.pdf

Hindawi Publishing Corporation Journal of Oncology Volume 2012, Article ID 412742, 5 pages doi:10.1155/2012/412742 Clinical Study RIT with 90Y-Ibritumomab Tiuxetan in Follicular Non-Hodgkin Lymphoma: Evaluation of Recent Outcomes in a Single Institution 1 ´ 1 ´ 1 Marcio Miguel Andrade Campos, Anel E. Montes Limon, Jose Marıa Grasa, Paola Lievano,2 Teresa Baringo,2 and Pilar Giraldo1, 3, 4 1 Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain 2 Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain 3 Instituto Aragones de Ciencias de la Salud (I+CS), Zaragoza, Spain ´ 4 Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER). Zaragoza, Spain ´ ´ Correspondence should be addressed to Pilar Giraldo, pgiraldo@salud.aragon.es Received 3 March 2012; Revised 6 July 2012; Accepted 2 August 2012 Academic Editor: Paul G. Richardson Copyright © 2012 Marcio Miguel Andrade Campos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Based on historical data we reviewed our hospital clinical database to analyse our updated information and therapy outcomes of follicular non-Hodgkin lymphoma (F-NHL) patients treated with 90Y-Ibritumomab tiuxetan. Patients and Methods. Between 2005 and 2011, 56 F-NHL patients were included in a clinical protocol conducted by a multidisciplinary team and treated in the same centre. Al